Oritavancin (INN also known as LY333328) is a novel semi-synthetic glycopeptide antibiotic being developed for the treatment of serious Gram-positive infections. Originally discovered and developed by Eli Lilly oritavancin was acquired by InterMune in 2001 and then by Targanta Therapeutics in late 2005.In December 2008 the FDA declined to approve it and an EU application was withdrawn. In 2009 the development rights were acquired by The Medicine Co.
This page contains content from the copyrighted Wikipedia article "Oritavancin"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
